RIPPLE

According to the Montreal Gazette (recognized source, score: 100/100), the Baszucki Group has funded a randomized controlled trial at the University of Oxford to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). The trial, supported by a £1.17 million grant, will evaluate both symptom progression and underlying biological mechanisms. This event directly affects the forum topic of clinical trials and research by introducing a new, potentially groundbreaking study into the field of mental health treatment. The funding enables the initiation of a scientifically rigorous trial, which could lead to new insights into the role of nutrition in mental health. If the trial demonstrates positive outcomes, it may influence future research priorities and treatment protocols in mental health care. The results could also spur further investment in non-pharmaceutical interventions for early-stage mental health conditions, potentially reshaping clinical guidelines and public health strategies in the long term. The causal chain begins with the funding announcement, which provides the necessary resources to conduct the trial. This leads to data collection and analysis, which, if successful, may result in peer-reviewed publications and policy discussions. The timing of these effects is primarily short to medium term, with outcomes expected within the next few years. Domains affected include healthcare, particularly mental health and nutrition, as well as health technology and innovation through the application of novel dietary interventions in clinical settings. The evidence type is an official announcement and event report. Key uncertainties include the trial’s success in meeting its primary outcomes and the extent to which findings will be adopted in clinical practice. Depending on the results, this could either reinforce or challenge current treatment paradigms. --- Source: [Montreal Gazette](https://montrealgazette.com/press-releases/business-wire/baszucki-group-funds-oxford-university-clinical-trial-of-ketogenic-therapy-for-early-psychosis/) (recognized source, credibility: 100/100)